Literature DB >> 33818106

Deconstructing Noncovalent Kelch-like ECH-Associated Protein 1 (Keap1) Inhibitors into Fragments to Reconstruct New Potent Compounds.

Jakob S Pallesen1, Dilip Narayanan1, Kim T Tran1, Sara M Ø Solbak1, Giuseppe Marseglia1,2, Louis M E Sørensen1, Lars J Høj1, Federico Munafò1, Rosa M C Carmona1, Anthony D Garcia1,3, Haritha L Desu4, Roberta Brambilla4,5, Tommy N Johansen1, Grzegorz M Popowicz6,7, Michael Sattler6,7, Michael Gajhede1, Anders Bach1.   

Abstract

Targeting the protein-protein interaction (PPI) between nuclear factor erythroid 2-related factor 2 (Nrf2) and Kelch-like ECH-associated protein 1 (Keap1) is a potential therapeutic strategy to control diseases involving oxidative stress. Here, six classes of known small-molecule Keap1-Nrf2 PPI inhibitors were dissected into 77 fragments in a fragment-based deconstruction reconstruction (FBDR) study and tested in four orthogonal assays. This gave 17 fragment hits of which six were shown by X-ray crystallography to bind in the Keap1 Kelch binding pocket. Two hits were merged into compound 8 with a 220-380-fold stronger affinity (Ki = 16 μM) relative to the parent fragments. Systematic optimization resulted in several novel analogues with Ki values of 0.04-0.5 μM, binding modes determined by X-ray crystallography, and enhanced microsomal stability. This demonstrates how FBDR can be used to find new fragment hits, elucidate important ligand-protein interactions, and identify new potent inhibitors of the Keap1-Nrf2 PPI.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33818106     DOI: 10.1021/acs.jmedchem.0c02094

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  4 in total

1.  Efficient Hit-to-Lead Searching of Kinase Inhibitor Chemical Space via Computational Fragment Merging.

Authors:  Grigorii V Andrianov; Wern Juin Gabriel Ong; Ilya Serebriiskii; John Karanicolas
Journal:  J Chem Inf Model       Date:  2021-11-11       Impact factor: 4.956

2.  Turning Nonselective Inhibitors of Type I Protein Arginine Methyltransferases into Potent and Selective Inhibitors of Protein Arginine Methyltransferase 4 through a Deconstruction-Reconstruction and Fragment-Growing Approach.

Authors:  Giulia Iannelli; Ciro Milite; Nils Marechal; Vincent Cura; Luc Bonnefond; Nathalie Troffer-Charlier; Alessandra Feoli; Donatella Rescigno; Yalong Wang; Alessandra Cipriano; Monica Viviano; Mark T Bedford; Jean Cavarelli; Sabrina Castellano; Gianluca Sbardella
Journal:  J Med Chem       Date:  2022-04-28       Impact factor: 8.039

3.  Importance of Binding Site Hydration and Flexibility Revealed When Optimizing a Macrocyclic Inhibitor of the Keap1-Nrf2 Protein-Protein Interaction.

Authors:  Fabio Begnini; Stefan Geschwindner; Patrik Johansson; Lisa Wissler; Richard J Lewis; Emma Danelius; Andreas Luttens; Pierre Matricon; Jens Carlsson; Stijn Lenders; Beate König; Anna Friedel; Peter Sjö; Stefan Schiesser; Jan Kihlberg
Journal:  J Med Chem       Date:  2022-02-02       Impact factor: 7.446

Review 4.  Targeting NRF2 to treat cancer.

Authors:  Jared Sivinski; Donna D Zhang; Eli Chapman
Journal:  Semin Cancer Biol       Date:  2021-06-05       Impact factor: 15.707

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.